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ABSTRACT
BDNF-Related Gene Expression of Laser Capture Microdissected Glutamate Neurons
from the Anterior Cingulate Cortex in Mouse Models of Autism Spectrum Disorder
by
Misty M. Owens

Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting social
behaviors. ASD affects 1 in 59 children with males affected more frequently. ASD is
postulated to result from excitatory and inhibitory neurotransmission imbalances. Brainderived neurotrophic factor (BDNF) signaling affects ASD by influencing
synaptogenesis, plasticity, and survival. Studying early in-utero neuropathological
changes within ASD requires the use of animal models. Expression of BDNF-associated
genes were analyzed within laser capture microdissected pyramidal neurons from the
anterior cingulate cortex of male and female BTBR and valproic acid mouse models. No
expression differences were found in any gene comparing the three groups. Gender
comparisons did identify differences in NTRK2 and EFNB2. Significant correlations of
gene expression were identified for male NTRK2 with EFNB2 and GRIN1 and EFNB2
with GRIN1 and female BDNF with GRIN1 expressions (p<0.05). Facilitating the
discovery of future ASD therapies hinges on identifying animal models recapitulating
molecular findings in ASD patients.
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CHAPTER 1. INTRODUCTION
Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that affects
both verbal and nonverbal communication, social interactions, as well as repetitive
activities or interests. According to the American Psychiatric Association DSM-5, autism
spectrum disorders include autism, Asperger’s disorder, and pervasive developmental
disorder not otherwise specified (1). Currently, 1 in 59 children are affected by ASD with
males affected four times more frequently at a rate of 1 in 42 (2,3). Children are often
diagnosed between two and four years of age, but many parents observe concerning
behaviors as early as six months (3). Abnormal social behaviors commonly observed in
human ASD include little eye contact, difficulty participating in typical conversations or
other social interactions, inability to share their feelings, and difficulties adjusting
behaviors for different social situations. Additional behavioral characteristics of the
disorder include repetitive behaviors or interests. While the severity of ASD is often
described as low-functioning to high-functioning based on the degree to which there is
disruption of daily life, this can be a very simplistic view of ASD. Each individual
symptom can vary to different degrees with each case making diagnosis difficult,
because currently only behavioral criteria are used. This difficulty in diagnosis makes
identification of molecular alterations associated with this disorder vital. Currently, there
is no cure for ASD, and treatment options are only available to manage peripheral
deficits i.e. mood associated with the disorder and are not designed to address the core
features of ASD.
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Epidemiology and Genetics of ASD
The etiology of autism is unknown but is thought to be multifactorial. Genetics
play a large role in the development of ASD as evidenced by studies that identify a 30%
concordance rate between dizygotic twins and as high as a 90% concordance rates in
monozygotic twins (4). These studies also show that genetics is not the only
contributing factor in the development of ASD as observed from the 10% of cases
where only one monozygotic twin is affected. These data indicate that environmental
exposures or nongenetic factors must influence the development of this disorder in
some way. Analysis of families with multiple children affected by ASD has yielded a 2%
to 4% recurrence risk indicating that the chance of having a second child with ASD is
greater than the typical population by 45 to 90 times. Additional analysis of this study
showed a negative correlation between ASD risk and the degree of relatedness (5).
Analysis of genomic sequencing for those affected with ASD and first order relatives
have not yielded a single gene responsible for the disorder, but instead has produced
hundreds of likely candidate genes (6,7). ASD is likely to be the result of multiple
genetic changes as opposed to a single gene, which are then amplified by
environmental exposures affecting neurological development (8). While no direct link
has been associated between ASD and other genetic disorders, studies have shown
that comorbidities are common among patients with ASD. The most common geneticlinked comorbidities include fragile X syndrome (50% - 60%), tuberous sclerosis (40% 50%), and epilepsy (8% - 30%) (9–11).
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Neurocircuitry of ASD
Social behavior is a complex phenomenon that requires the coordination of
multiple neuronal structures. It requires accurate sensing, processing, and interpreting
of verbal and nonverbal social behaviors displayed by others as well as situational and
cultural norms. Together, this social-behavioral brain circuitry is responsible for
controlling emotions and determining behavioral phenotypes in response to current
emotional states and the perceived behaviors of others (12). Due to the behavioral
phenotypes of ASD patients in regard to behavioral and social aspects, it is reasonable
to conclude dysmorphias are likely present within the social-behavioral brain circuitry. It
has been postulated that the brain dysfunctions of ASD are not confined to discrete
structures, but instead affect multiple parts of this circuit. The coordinated functions of
the limbic lobe, prefrontal cortex, and anterior cingulate cortex are believed to influence
social behavioral phenotypes based on internal and external emotional states. While
distinct functions can primarily be associated with specific structures, the entire circuitry
contains reciprocal connections and as a whole form the social-behavioral brain circuit
allowing for social cognition (13).
Incoming sensory signals from all modalities, with the exception of the olfactory
system, travel along afferent neurons that ascend the spinal cord and synapse at the
thalamus within their respective nuclei. The thalamus serves as the relay station from
peripheral sensory receptors to the cerebral cortex for incoming sensory information.
Processed sensory inputs then travel from the primary sensory cortices to the 13
amygdalar nuclei located within the medial temporal lobe. The amygdala is a key
structure in the social circuitry due to its amplification and additional processing of
10

inputs from social sensory modalities that are significant to self-regulation. The five main
amygdalar nuclei involved in the social-behavior circuitry include the medial, lateral,
central, basal, and accessory basal nuclei. Specifically, the medial nucleus receives
information in regard to both positive and negative social stimuli. The lateral nucleus
receives information associated with visual stimuli in regard to facial expressions and
other nonverbal communication as well as auditory stimuli. The manifestation of
emotional responses due to sensory inputs is due to amygdalar influence over the
autonomic and endocrine systems via its connections from the central nucleus to the
brainstem and hypothalamus (13,14). Finally, the amygdala inputs into the motor
system to affect motor outputs based on emotional states due to the basal and
accessory basal nuclei’s connections with the ventral striatum (12). Within the limbic
lobe, the hippocampus functions to convert short-term memories to long-term
memories, and the hypothalamus releases hormones and signaling molecules into the
body. The amygdala and the hippocampus both have intricate connections with the
mesolimbic dopamine system to provide input on the reward pathways of the brain
based on incoming stimuli. The connections with the amygdala allow for internal
emotional states to be highly integrated with these processes and influence both
structures.
In addition to the limbic system, the social-behavior brain circuitry is also
controlled by multiple structures of the cognitive prefrontal cortex, in particular the
orbitofrontal cortex (OFC). This area of the brain is located on the ventral surface of the
frontal lobe. The OFC receives extensive connections from multiple modalities and all
limbic lobe structures. Connections specifically associated with the amygdala and
11

thalamic nuclei allow for input into the management of self-regulation in social situations
based on internal emotional states and external stimuli associated with past
experiences. In addition, the OFC has the ability to influence motor output based on
emotional states due to its connections with structures like the caudate and ventral
tegmental area (12).
The anterior cingulate cortex (ACC) is an agranular structure within the medial
prefrontal cortex that is directly superior to the genu of the corpus callosum. This
structure includes Brodmann areas 24, 32, and 33. It has extensive connections with
structures of the limbic lobe including the amygdala and thalamus as well as additional
prefrontal cortex structures like the OFC (15). Due to long range neuronal connections
from the ACC to the amygdala and the projections from the midline and intralaminar
thalamic nuclei, which also connect to the amygdala, the ACC is thought to play a role
in emotional vocalization and speech production. In addition the intricate connections
between the ACC and the OFC is thought to influence the emotional self-related
aspects of social situations (16). Additional connections allow for internal emotional
changes to provide input into the endocrine system and influence motor outputs. In
addition, due to influences over the endocrine system, it is thought that the ACC could
also influence internal emotional changes (12). Additional functions associated with the
ACC include reward expectancy, decision-making, empathy, and emotion (16).
Neuroimaging studies have consistently documented abnormalities of the ACC in
ASD. Reduced blood flow in the ACC has been demonstrated during emotionalrecognition studies in individuals with ASD as compared to typically developing (TD)
(17). Additional topography studies using small cohort of male and females together
12

(N=12) have revealed decreases in the serotonin receptor 5-HT2A throughout the
cingulate cortex (18). MRI analysis of seven patients with ASD revealed decreases in
resting ACC volume as well as decreased metabolic activity of the area (19).
Additionally, functional MRIs have revealed hyperactivation of the anterior cingulate
cortex during social targeting (20). Multiple neuroimaging studies comparing ASD
individuals to TD controls have shown decreased functional activity within the ACC
(13,21–24). Observations of the social circuitry in ASD has led to postulations that
altered numbers of short and long-range connections throughout the entire system,
desynchronization of cortical activity, and altered developmental trajectories may be
present in brain areas associated with social behaviors.
While the structures mentioned here are known to play a central role in the
social-behavioral brain circuit, it is highly probable that additional structures influence
neuronal development and behavioral phenotypes due to extensive bidirectional
connections.

Neuropathology of ASD
While the core symptoms of ASD fall into three primary categories, the
neuropathologies that result in these behaviors are extremely vast. Research has
identified numerous neuropathological abnormalities in ASD patients. Determining the
exact developmental abnormality associated with specific phenotypic manifestations
has proven challenging due to the multitude of symptoms that can arise from the same
developmental anomaly or the large number of developmental abnormalities that can
result in the same behavioral phenotype. In addition, due to the multitude of subsets
13

within the ASD disorder, it is highly likely that both severity of pathology as well as
various different abnormalities leads to the development of ASD subsets. Finally, ASD
is a lifetime disorder with different neuropathological findings associated with different
age groups. It is still debated whether the pathological findings in adolescence and
adulthood are due to continuous pathology or secondary effects of early abnormalities
from childhood. The nature of the disorder makes identifying specific pathological
changes difficult, because symptoms may or may not be present depending on the
subset and age of the evaluated donors.
Analysis of ASD whole brain weights and volumes in addition to specific
structural studies have been conducted using MRI and postmortem studies comparing
ASD brains to TD samples. Analysis of head circumference (HC) by Bailey, et. al
revealed ASD infants had normal measurements at birth that increased at an
accelerated rate over 14 months resulting in abnormally large HC measurements. The
increase in HC was shown to correspond to increases in cerebral grey matter volumes
confirmed with MRI analysis (25). Additional MRI studies and postmortem brain analysis
confirmed these findings and identified an age-related reversal in brain volumes leading
to significantly smaller ASD brains in adolescence and adulthood (26). Analysis of
subcortical structures have revealed volumetric increases of the amygdala as compared
to decreases of the cerebellum and motor system structures including the caudate
nucleus, putamen, globus pallidus, and nucleus accumbens (26–29). Atypical activation
of the corpus callosum observed in fMRI studies have indicated possible morphological
changes of this structure (30).
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Cortical organization of white and grey matter has displayed abnormal
developmental patterns in ASD. Analysis of Brodmann areas 9, 21, and 22 all revealed
increases in the ratio of white matter to grey matter specifically within the short-range
fibers of the outer subcortical layers revealed using MRI studies (27,30). Imaging
studies have detected ectopic grey matter abnormalities as well as alterations in grey
matter volume specifically in the parahippocampal gyrus, cingulate, putamen, and
thalamus (27,31). Analysis of neuronal organization has led to the discovery of atypical
organization of peripherin-positive fibers within the dentate nucleus (27).
Postmortem brain tissue samples have been used to uncover neuronal
abnormalities within ASD brains. Small sample studies of the cerebral cortex,
hippocampus, amygdala, entorhinal cortex, and ACC have identified increased cellular
densities. The pyramidal neurons were found to be significantly decreased in size but
often have extensive branching patterns (27,30,32). In addition, Hutsler et. al reported
increased dendritic spine densities on pyramidal neurons within the superficial layers of
the temporal lobe (27,30). Increases in parvalbumin positive GABAergic interneuron
densities have also been detected in the CA1 and CA3 regions of the hippocampus
(27). Alternatively, decreased cell numbers were observed in the motor system,
specifically the caudate nucleus, putamen, globus pallidus, and nucleus accumbens, as
well as the amygdala. Within the posteroinferior cerebellar region, Purkinje cell numbers
were also found to be decreased (26,27). Minicolumns consists of roughly 100 neurons
and makeup functional units. Postmortem analysis of these structures within BA 9, 21,
and 22 have revealed increased numbers of narrower columns located closer together
(27,29). Age related changes have also been observed in cellular analysis including
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abnormally large neurons within the band of Broca, cerebellar nuclei, and inferior olives
as well as an increased number in the cerebral cortex in children as compared to
decreases in size and numbers within adults (27). A limitation observed within all
studies of ASD utilizing both postmortem tissue and imaging studies are low sample
numbers. The availability of ASD postmortem tissue is extremely limited and obtaining
MRI data from ASD patients is very difficult due to the restrictive nature of the test. Low
sample sizes utilized in ASD studies may limit extrapolation of the data to the ASD
population.

Synaptic Transmission in ASD
All functions within the body rely on communication between cells. Multiple cell
types can be found throughout the body and within the brain including excitatory and
inhibitory neurons, microglia, astrocytes, and oligodendrocytes. The intricate
connections between these cells and the highly controlled communication via synaptic
transmission allows the passage of signals from points of origin to the destination points
due to cellular changes in morphology, molecular aspects, and electrical changes that
permit all actions carried out in the body (33).
Neuronal communication occurs at synaptic junctions via neurotransmitters. The
synapse is formed by the close interactions of the presynaptic neuronal axon and the
postsynaptic dendrite. While these processes are not touching, they are extremely close
in proximity, and the space between them is known as the synaptic cleft (34).
Communication between these two cells occurs due to electrical signaling propagating
down the presynaptic neuron causing the release of neurotransmitter molecules from
16

the presynaptic terminal into the synaptic cleft. These molecules then transverse the
cleft and bind to their respective receptors found on the postsynaptic membrane. Based
on the function of the activated receptors, multiple neuronal and protein changes can
lead to the generation of action potentials, transcription, translation and modification,
synaptic plasticity, and a host of other functions. The mechanisms occurring within a
single synapse is quite complex involving multiple cells and signaling networks. A single
neuron must integrate information from hundreds of excitatory and inhibitory synapses
to determine if signals should continue to be propagated.
While neurons have been the main focus for many cellular studies, the
contribution of additional cell types are just as important to maintain healthy connections
and tight regulation of cellular communication. Astrocytes and microglia are two types of
glial cells found within the brain. Previously it was thought that both cell types functioned
only in supportive roles with regard to neuronal health and environmental maintenance,
respectively. However, it has recently been shown that both cell types play a role in
signaling within the neuronal circuitry. Astrocytes within the brain have tight interactions
with both neurons and the vasculature. The connections associated with neurons occur
at the synapse, where the astrocytic processes interact intimately with the synaptic cleft
as well as the presynaptic and postsynaptic neurons forming the tripartite synapse (35).
The strictly supportive function previously assumed of these cells was due to the
“bridge” they form between neurons and the vasculature allowing astrocytes to pull the
needed nutrients from the blood into the neuronal environment. It is now known that
they also assist with neurotransmitter reuptake to ensure the clefts are kept clear of
excess excitatory transmitters to prevent over stimulation of the receptors. More
17

recently, it has been determined that astrocytes may play a greater role in cellular
circuitry due to their ability to release gliotransmitters into the synaptic cleft (35,36). The
microglia subtype is found within the central and peripheral nervous systems. This cell
type, previously associated with immunological functions, is known to activate and
respond quickly due to changes in its environment. Studies have recently found that
upon activation, these cells can communicate with astrocytes resulting in the release of
astrocytic glutamate causing activation of metabotrophic glutamate receptors (mGluR)
on neurons (37,38). Another type of glial cell is the oligodendrocyte. These cells encase
neuronal axons in myelin sheets affecting the speed of action potential propagation as
well as provide metabolic support and maintain the K+ ion concentrations in the
extracellular matrix (39,40).
Due to the intricate interactions of all cell types within the cellular circuitry,
pathologies at any number of locations could have detrimental effects on normal brain
development. Studies have shown multiple pathological changes within neuronal
circuits of ASD patients that could result in abnormal development and function.
Postmortem ASD studies have revealed increased numbers of dendritic spines possibly
resulting from the observed decreases in components of the autophagy system versus
increases in the autophagy substrates (30,41). Pluripotent stem cell analysis has also
revealed reductions in neurotransmitter release and abnormalities in synaptic function
(42–44).
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Excitatory and Inhibitory Imbalance
It has been suggested that the neuropathology of ASD may be the result of an
imbalance between excitatory synaptic interactions and the inhibitory connections (45).
Glutamatergic neurons are the major excitatory cells in the brain that upon activation
release the primary excitatory neurotransmitter glutamate. Activation of glutamatergic
neurons are influenced by both excitatory and inhibitory signals. The release of
glutamate occurs from the presynaptic neuron and is controlled by presynaptic
influences from multiple cellular components. Excessive glutamate levels can have
devastating effects resulting in hyperexcitability (46). The primary inhibitory
neurotransmitter within the body is gamma-aminobutyric acid (GABA). Binding of GABA
can inhibit downstream action potentials from glutamatergic neurons. The glutamate
receptor GluR6 controls the release of GABA through pre-synaptic interactions (47).
The activation of both GABAergic and glutamatergic circuits regulates neuronal cellular
migration and neurotransmission.
It is thought that an imbalance in the glutamatergic and GABAergic systems may
be present in the social circuitry of ASD. Key support for this theory includes reductions
in the expression of GABRA1, which encodes GABA receptor subunits as well as
reductions in the amount of GABA within brain structures found within ASD patients
(48,49). Significant decreases of GABAA and GABAB receptors have been observed in
the ACC and hippocampus of ASD subjects compared to TD controls (50–53). Fatemi
et. al conducted protein analysis of GAD67 and GAD65, which are proteins vital for
GABA neurotransmission in the brain. Using postmortem ASD brain samples as
compared to TD brains, they found a 50% decrease in both proteins within the parietal
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and cerebellar cortices (53). Another study demonstrated an increased number of
dendritic spines on glutamatergic neurons with no corresponding increase in cell
numbers using postmortem human tissue from frontal, parietal, and temporal lobes (30).
Additional implications of excitatory/inhibitory dysregulation include an imbalance in the
serum glutamate/GABA ratios and elevated levels of glutamate and glutamine in the
posterior ACC in children with ASD (54,55).

BDNF Pathway
Brain-derived neurotrophic factor (BDNF) is part of the neurotrophin family that
includes nerve growth factor, neurotrophin-3, and neurotrophin-4/5 (56). BDNF is a vital
component for the development and maintenance of the nervous system. It first appears
during prenatal development and is maintained throughout adulthood. It serves many
functions within the body affecting neuronal growth, proliferation, morphogenesis,
maturation, cellular plasticity, migration and survival, as well as mediating long-term
potentiation and cell death (56–59). BDNF and the downstream pathways it activates
are likely key modulators of the balance between excitatory and inhibitory synapses
(59,60). The functions of BDNF transpire due to binding with the low-affinity
neurotrophin receptor p75 and the high-affinity receptor full-length tyrosine receptor
kinase B (trkB) encoded by NTRK2 (56). Binding between BDNF and trkB receptors
form a homodimer to allow for cross tyrosine phosphorylation of the intracellular
receptor portions resulting in the activation of three different signaling cascades:
mitogen-activated protein kinase (MAPK), phospholipase Cγ (PLCγ), and
phosphatidylinositol 3-kinase (PI3K) (59).

20

The MAPK pathway is responsible for neuronal survival and growth and plays a
vital role in protein synthesis-dependent plasticity. Upon phosphorylation of the trkB
tyrosine Y515 residue, the MAPK pathway becomes activated leading to the recruitment
and activation of multiple proteins including Shc, Grb2, SOS, and Ras. Upon
phosphorylation of Ras, multiple downstream kinases are activated including MAPK.
Once activated, MAPK influences neuronal survival, growth, and plasticity by activating
CREB and increasing phosphorylation of eukaryotic initiation factor 4E (59,61). The
PLCγ pathway is activated due to the phosphorylation of the Y816 residue on trkB
leading to the formation of diacylglycerol (DAG) and inositol 1,4,5-trispohsphate (IP3).
The formation of IP3 leads to an increase in the amount of Ca2+ within cells due to the
release of the intracellular stores. This increase of Ca2+ in conjunction with DAG
proteins leads to the activation of plasma membrane transient receptor potential
canonical subfamily channels ultimately resulting in synaptogenesis (59). In addition,
the increases of intracellular Ca2+ in conjunction with the activation of NMDA receptors
result in the transport of transducers of regulated CREB activity, specifically CRTC1,
from the cytoplasm to the nucleus. Once in the nucleus, CRTC1 causes
phosphorylation of CREB resulting in additional transcriptional activity aiding the MAPK
pathway in increased dendritic development (62). The activation of the PI3K/AKT
cascade has downstream effects on the mammalian target of rapamycin (mTOR)
complexes. Activation of mTOR and its downstream targets help to control many
neuronal aspects including synaptic formation, protein translation, proliferation,
differentiation, survival, and autophagy (63). Expression changes of the mTOR pathway
are hypothesized in ASD due to the relationship with tumor suppressor genes (TSC).
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Studies showing TSC1/TSC2 reductions contribute to increased mTOR expression
resulting in the display of social behavior deficits similar to ASD within these patients
(64). Overexpression of mTOR in mice in-utero have shown increases in the size of
the cell soma and smaller, abnormally shaped neurons when expression rates are
decreased (65). Increases in cortical neuronal dendrites leading to the hyperconnectivity
between social circuit brain areas is thought to result in the ASD phenotype (66). The
mTOR protein forms the activating subunit of two complexes: mTOR Complex 1
(mTORC1) and mTOR Complex 2 (mTORC2). The initial activation of PI3K leads to the
phosphorylation of AKT resulting in increases of protein synthesis through mTORC2
(67). Activation of mTORC1 increases dendritic arbor in length and thickness (68). It is
possible that global changes in the signaling pathway of mTOR that impact synaptic
densities may exist in ASD. Downstream glutamate release of the mTOR pathway is
regulated to prevent excessive stimulation leading to excitotoxicity. The metabotropic
glutamate receptor 8, encoded for by GRM8, is found on the presynaptic terminal. Upon
binding to glutamate, GRM8 prevents additional glutamate release by inhibiting adenylyl
cyclase.
In addition to influencing glutamatergic neurons, activation of BDNF and trkB
signaling also influences GABAergic neurotransmission. Glutamate within the brain
influences the release of BDNF to allow for increased trkB binding which in turn
influences synaptic transmission and plasticity by pre- and post-synaptic binding (62).
Binding of GABA to the GABA receptors influence downstream action potential
potentiations. In GABAergic cells, BDNF binding to trkB induces glutamic acid
decarboxylase (GAD) expression (69). GAD is the rate controlling enzyme found within
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GABAergic neurons within the brain that regulates the formation of GABA by
transporting glutamate into the cell and converting it into GABA by consuming an H+ ion
(48,70). The interplay of BDNF in the release of glutamate and the rate of GABA
formation plays a fundamental role in transmission and activity-dependent plasticity of
neurons. In addition, it affects glutamatergic synapses by enhancing depolarization
leading to the release of glutamate and increasing the expression of glutamate
receptors i.e. GluR. Studies have found that the BDNF levels within the brain and serum
of ASD individuals are increased as compared to healthy controls (71).
Many downstream genes associated with the activation of BDNF-NTRK2 are
highly influential in the regulation of synaptogenesis, plasticity, and cell death of both
excitatory and inhibitory synapses. The N-methyl-d-aspartic acid (NMDA) receptors can
be found on presynaptic and postsynaptic neurons. NMDA-receptors are ionotropic
glutamate receptors that are vital for neurotransmission, long-term potentiation (LTP),
and refinement of the excitatory connections. In-vitro studies of BDNF binding to trkB
was shown to enhance NMDA receptor expression (72). A functional NMDA-receptor
that binds to glutamate cannot be formed without the obligatory GRIN1 subunit. A
second downstream molecule associated with glutamatergic synaptic remodeling is
ephrin. During late development, EphrinB2 is responsible for trafficking and anchoring
ionotropic glutamate receptors, including NMDA receptors, to the surface of the cell
membranes. Dysregulations of this protein have demonstrated an increased likelihood
that the ionotropic receptors will be internalized back into the cell resulting in weaker
signaling and a decreased chance an action potential will be propagated (73).
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Additionally, it was shown in mice that increased ephrinB2 levels have been directly
associated with increased spine densities in the hippocampus (74).
While BDNF-trkB signaling is one of the main activation pathways for MAPK,
PI3K, and PLCγ signaling, it is important to know that multiple hormones and cytokines
like insulin-like growth factor 1 and interleukin-6 can also activate these cascades
(75,76). Abnormalities within these additional alternative cell-signaling pathways may
lead to new or compounding changes within these circuits that can increase any
pathophysiological changes already occurring from dysregulation of BDNF-trkB
signaling. This, in part, could explain the extreme heterogeneity of symptoms and
neuropathology observed in ASD.

Sex Related Differences
Over the last few decades as the prevalence of ASD has increased, the ratio of
males to females within the ASD spectrum has remained four times greater. However,
this ratio can vary greatly when analyzing different ends of the spectrum. When
comparing high-functioning cases the male to female ratio can be as high as 18:1 as
compared to a 2:1 ratio when observing low-functioning cases (77). Sex-based
differences must be present to explain the male-bias observed in this disorder. Little
research has been done to study ASD in females. Current studies of females often look
at differences between females with ASD as compared to typically developing subjects
or mixed gender groups. Very few studies have been carried out comparing female ASD
subjects to male ASD subjects.
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The core symptoms normally associated with ASD appear to present differently
when comparing male and female cases. Males tend to display more repetitive
behaviors and scored higher in systemizing aspects as compared to females and TD
males based on parent/teacher assessments of children with ASD. In addition, teacher
reports indicate that males tend to display more behavioral issues such as ADHD and
are less likely to display prosocial behaviors (78). Females tend to display less severe
communication and social deficits when compared to males that are affected with ASD
(79). One of the few gender studies in ASD, Scharz et. Al, compared blood levels of
multiple analytes between male and female ASD with controls to find that IL-1β
expression was significantly increased in both males and females when compared to
controls (80). In addition, they found that certain analytes were expressed differently in
males as compared to females. For example, BDNF expression was significantly
elevated in female serum when compared to controls, but was not significantly different
in males (80). In addition, using in vivo voxel-based morphometry, ASD females showed
a greater reduction in grey matter within the amygdala, cerebellum, parahippocampus,
and cingulate as compared to ASD males that tested at the same ASD severity (81).
This indicates that females may have a “protective mechanism” from developing autism
that requires more severe pathological changes as compared to males.

Mouse Models
Animal models are an essential tool in studying any psychiatric and neurological
disorder. In ASD, the neurological changes leading to the observed behavioral
phenotypes almost certainly occur during prenatal development. However, there is no
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accepted ASD animal model that is embraced by the research community. It has been
extensively debated that the use of mice or rats to accurately demonstrate ASD-like
behaviors may not be valid thus leading to a plethora of animal models. In the proposed
study, two currently available mouse models will be used to determine if the BDNFrelated alterations seen in human ASD can be identified in any or all of the models to be
used for future mechanistic studies. The two models in the proposed study have very
different etiological starting points but display similar social behavior deficits in the
literature. The two groups include a genetically bred model and a model in which a
substance is administered during gestation. The control mouse strain C57BL/6J (C57) is
the most common mouse strain used in research. It is considered a control model in
ASD due to the observed behavioral characteristics that include fear learning, physical
activity, cognitive ability, and most importantly a social preference for other mice as
compared to objects (82,83).
The BTBR T+tf/J mouse strain (BTBR) is a genetically inbred mouse between
black and tan mice originally designed for studies in diabetes that exhibits deficient
social interaction as well as repetitive behaviors (84). BTBR’s unique dark fur with areas
of hair loss results from the knockout of the inositol triphosphate receptor 3 (Itpr3).
When comparing BTBR and C57 control mice, the genetic changes resulted in
alterations in taste and food preferences, a mutation in the glutamate antagonist
kynurenine 3-hydroxylase, and identification of autism-relevant commissural
morphological alterations (6,85). Due to the presence of all the core symptoms of ASD,
it is arguably the model with the most support in the ASD literature. In addition to social
and repetitive behavioral changes, imaging studies have shown that this inbred strain
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has structural anatomical changes within the hippocampus as well as an absent or
thinned corpus callosum mimicking the reduction of corpus callosum volume in human
ASD (67). Further studies between the differences within the BTBR and C57 model
have revealed a single nucleotide polymorphism that may affect genes important in the
control of the excitatory glutamatergic neurons (8). In addition, these mice display a
reduction in hippocampal neurogenesis, increased ACC expression of oligodendrocyte
precursors, as well as changes in proteins involved in neural development and plasticity
including BDNF (86).
The valproic acid (VA) mouse model is used to analyze effects that
environmental exposures can have on offspring. Valproic acid is a common antiseizure
medication and exhibits an association with ASD in offspring if used during pregnancy
(87). Phenotypic changes are brought about due to the wrapping or unwrapping of
chromatin from histones due to the addition or removal of acetyl groups via histone
acetyltransferases and histone deacetylases, respectively (88). Valproic acid acts as a
histone deacetylase inhibitor within the body that leads to increases in the acetylation of
chromatin ultimately leading to increases in cell death (89). While the exact
mechanisms are still unknown, valproic acid is thought to affect the development of
neurons contributing to imbalances in excitatory and inhibitory neurons. Studies
injecting mice with VA at varying gestational timepoints revealed significant decreases
in neuronal counts obtained via imaging studies for those offspring of dams injected with
developmental time frames corresponding to the start of neuronal development (90).
This model requires an injection of valproate into pregnant C57 dams on gestational day
12.5 (E12.5).
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Previous studies using VA models have been conducted providing support of
being a good ASD model. Previous analysis using rats to evaluate the excitatoryinhibitory systems, found that the expression of GAD and the γ2 subunit of GABAA
decreased in a dose-dependent manner upon valproic acid treatment (91). The
offspring of valproic-acid treated rats received a lowered social interaction score,
displayed decreases in juvenile play and reduced social exploration as well as
increased repetitive behaviors (52). Additionally, they found in the valproic acid rat
model that the social behaviors were present in male offspring more than females.
The current study was performed to analyze gene expressions in the BTBR and
VA mice models as compared to C57 controls. Both BTBR and VA mice display social
behavior deficits including decreased social interaction and communication as well as
repetitive behaviors resembling the core symptoms of human ASD. Laser capture
microdissection was utilized to obtain tissue samples enriched with excitatory pyramidal
neurons from the ACC given the hypothesis that ASD results from imbalances in
excitatory and inhibitory neuronal transmission. Genes associated with the BDNF
pathway were analyzed due to the vital role it plays in neuronal development,
maintenance, and function especially with regard to glutamatergic transmission.
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CHAPTER 2. METHODS
Animals
Initial C57BL/6 (C57) (strain # 000664) and BTBR T+Itpr3tf (strain # 002282)
breeding mice were obtained from the Jackson Laboratory. All mouse lines were
maintained at East Tennessee State University’s Animal Facility. Mice were housed
individually in an environment-controlled room on a 12-hour light/dark cycle and had
continual access to food and water. Breeding between all mice consisted of a 10-day
cycle. Male mice were placed in the female’s cage and allowed to urinate before being
returned to their original cages the day before a breeding cycle was started. On day one
of the breeding cycle, the starting weight of the females were obtained, and the male
mouse was placed into her cage for three days. Seven days after removal of the male
mouse, the female’s weight was taken and considered pregnant if an increase of 2
grams from the starting weight was observed. Pregnant C57 and BTBR mice were left
undisturbed until after birth. To create the valproic acid model, pregnant C57BL/6 dams
were given a 600 mg/kg i.p. injection of valproic acid at E12.5. Injected dams were
observed to determine if valproic acid initiated an analgesic effect in which the mouse
sleeps. This effect affirms that the drug sufficiently entered the bloodstream of the
pregnant mouse. After birth, pups were left caged with the mother until postnatal day
21. All animal procedures were approved by East Tennessee State University
Institutional Animal Care and Use Committee.
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Tissue Acquisition
Mice were sacrificed at postnatal day 21 (P21). Brains were removed and frozen
at -80°C until tissue acquisition. At the time of tissue acquisition, brains were transferred
to a Leica Cryocut machine in a cooler between ice packs. Cryocut temperature was
kept between -14°C and -17°C. Tissue samples were placed in Cryocut for one hour.
O.C.T. Compound was used to adhere the brain onto a mounting block with the frontal
lobe accessible to allow coronal sections to be obtained. The Allen Brain Mouse
Reference Atlas from the Allen Institute (76) was used to identify the lateral ventricles
and corpus callosum as anatomical landmarks indicating the presence of the ACC. To
ensure consistent ACC location, fifty 50μm sections were removed. Confirmation of
anatomical structures was obtained by visualization of a 10μm section with a cresyl
violet stain followed by ethanol washes and xylene dehydration (Figure 1).

B
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Figure 1. Visualization of anatomical structures used to identify the ACC in coronal
mouse brain sections. (A) Allen Mouse Brain Reference Atlas (76) shows labeled
corpus callosum and lateral ventricles used to identify ACC in tissue samples. Anterior
cingulate cortex is indicated by ‘ACA’ and light green shading directly superior to the
corpus callosum. (B) Coronal section (40μm) from a test subject displaying the same
anatomical structures from (A). Neurons were obtained from the ACC above the corpus
callosum up to the black diagonal lines indicating the ACC boundaries.
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Two methods for slide preparation were used to obtain 10μm slides. The first
method required superfrost plus microscope slides to be placed in the Cryocut for one
hour to allow the temperature of the slide and tissue to reach equilibrium. After tissue
acquisition, the slide remained in the Cryocut until all 10μm tissue sections were
obtained. The slides were then immediately placed in a desiccator at 4°C for 30 minutes
after which they were removed from the desiccator and stored at -80°C until further
analysis. The second method left slides at room temperature prior to tissue acquisition
and placed them in a cold slide box on ice after tissue retrieval until all 10μm slides
were obtained. The slides were then placed in an air-tight chamber at 4°C for one hour
after which the entire desiccator was placed at -80°C overnight. Care was taken to open
the desiccator in the -80°C to prevent ice crystallization of the tissue due to exposure to
room temperature air. Slides were stored at -80°C until analysis.
To obtain 40μm tissue samples, superfrost plus microscope slides were kept at
room temperature. The backs of slides were briefly warmed with fingers immediately
before tissue acquisition then placed in a slide box on ice. After all tissue was obtained,
slides were placed in an air-tight desiccator and left at 4°C overnight. They were then
removed from the desiccator and stored at -80°C until analysis.
Whole tissue punches 2mm in diameter were taken from mice, as needed, to be
used as a positive test control for PCR analysis. Tubes and a 2mm punch were placed
in the Cryocut one hour prior to allow equilibrium in temperature with the tissue
samples. Four punches were obtained from a 50μm thick coronal section. Tubes were
then transferred to -80°C in a cooler between ice packs and extreme care was taken not
to warm the sides of the tubes.
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A cresyl violet stain with an image taken using a macroscopic camera on a light
box was used for area mapping (Appendix B). The procedure involved removing
previously sectioned 40μm tissue on glass slides from -80°C and placing in a ventilated
hood at room temperature for 20 minutes. Slides were then stained using the following
protocol: xylene (3 minutes), xylene (3 minutes), 100% EtOH (1 minute), 100% EtOH (1
minute), 95% EtOH (1 minute), 70% EtOH (1 minute), distilled H2O (dip), cresyl violet
(15 minutes), distilled H2O (30 seconds), 70% EtOH (1 minute), 95% EtOH (1 minute),
100% EtOH (1 minute), 100% EtOH (1 minute), xylene (3 minutes), xylene (3 minutes).
Slides were left to dry in the hood overnight. Fisherfinest Premium Cover Glass and
Fisher Scientific Paramount were used to coverslip tissue. Images of each sample were
obtained using a macroscopic camera system with a lightbox and MCID software to
confirm identifying landmarks and ACC (Figure 2).
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Figure 2. Images of (40μm) coronal brain sections used for ACC conformation.
Presence of corpus callosum, lateral ventricles, longitudinal fissure, and ACC are visible
in all image. Identification number in the top left corner indicates the corresponding
sample. Male samples are found in the left column and females in the right column. (AB) Control C57. (C-D) BTBR (E-F) Valproic acid

Laser Capture Microdissection
Glutamatergic pyramidal neurons were identified by staining 10μm tissue
sections using a short cresyl violet stain followed by dehydration of the tissue with
Thermo Fisher Scientific Arcturus Dehydration Components. Tissue slides were
removed from -80°C and placed in cold 75% EtOH followed by distilled nuclease free
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H2O for 30 seconds each. Tissue was stained using 150μl of Thermo Fisher Scientific
Arcturus HistoGene Staining Solution for 45 seconds followed by distilled nuclease free
H2O, 75% EtOH, 95% EtOH, and 100% EtOH washes for 30 seconds each. Slides were
then dehydrated in xylene for five minutes. Tissue was placed in hood to allow for the
evaporation of xylene then transferred in a desiccator to the laser capture
microdissection (LCM) room.
LCM was performed using an ArcturusXT instrument. Tissue was visualized at
40x magnification and the ACC was located by a diagonal line from the horn of the
corpus callosum to the longitudinal fissure (Figure 1). Pyramidal neurons were identified
based on their triangular morphology at 40x magnification (Figure 3). Neurons were
extracted onto CapSure macrocaps using a 12μm spot size and an infrared (IR) laser.
Confirmation of neurons was obtained by viewing the cap at 20x magnification (Figure
3) as well as visualizing the sample tissue at 40x magnification. A total of 500
glutamatergic pyramidal neurons were obtained for each sample. Cap was viewed
under dissecting microscope, and any excess tissue attached was scraped off using a
syringe needle. Cap was placed on a 0.5ml tube containing 55μl of extraction buffer
from a Thermo Fisher Scientific Arcturus PicoPure RNA Isolation Kit and incubated at
42.0°C for 30 minutes. The cap was stored upside down at -20°C until further analysis.
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Figure 3. Glutamatergic neuron collection utilizing laser capture microdissection. (A)
Visualization of cells within the grey matter of the ACC. The arrows indicate pyramidal
glutamatergic neurons identified by a cresyl violet stain (40x magnification). (B)
Glutamatergic neurons that have been cut from the tissue sample and adhered to a
polymer cap (20x magnification).

RNA Purification and cDNA
Neurons obtained through LCM were RNA purified using an Arcturus Picopure
RNA Isolation Kit. Filter columns from kit were conditioned with 250μl of conditioning
buffer (CB) at room temperature for 5 minutes then centrifuged at 16,000g for one
minute. CB was then discarded from column. A total of 55μl of 70% EtOH was placed in
tubes containing the neuron samples to create a 1:1 ratio of EtOH and extraction buffer.
Tubes containing tissue samples were mixed by pipetting up and down. The extractEtOH mixture was transferred to the pre-conditioned column and centrifuged for 2
minutes at 100g followed by a 30 second centrifugation at 16,000g. This sequence of
centrifugation was repeated to allow for maximum binding. Next, 100μl of wash buffer 1
(W1) was pipetted onto the column and centrifuged for one minute at 8,000g. A DNase
treatment was then prepared in a separate tube by adding 5μl of DNase I to 35μl of
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Buffer RDD, from the Qiagen RNase-Free Dnase Set, per sample and was mixed gently
by inverting the tube. A total of 40μl Dnase treatment was pipetted directly onto the
column and allowed to incubate at room temperature for 15 minutes. Then 40μl of W1
was added to the column and centrifuged for 15 seconds at 8,000g. Next, 100μl of wash
buffer 2 (W2) was added to the column and centrifuged for one minute at 8,000g and
followed up with another 100μl of W2 and centrifugation for two 2-minute cycles at
16,000g each. The column was then transferred to a new 0.5ml tube where 16μl of
elution buffer was added directly to the center and allowed to incubate for five minutes
at room temperature. The column was then centrifuged for one minute at 1,000g
followed by one minute at 16,000g.
To purify punches to use as reaction controls, 200μl of extraction buffer and
200μl of 70% EtOH was added to the tube containing the punched tissue. Tubes were
placed on ice then vortexed to ensure tissue completely dissolved in liquid. The same
protocol used for neuron RNA purification was followed for punches with the exception
that the amount of elution buffer used was increased to 18μl.
cDNA was made using an Invitrogen SuperScript III Platinum Two Step qRTPCR Kit. For each sample, a mixture of 10μl of 2x RT Reaction Mix, 2μl of RT Enzyme
Mix, and 8μl of purified RNA was created and ran on a BioRad thermocycler for 10
minutes at 25°C, 30 minutes at 50°C, and 5 minutes at 85°C. Tubes were then removed
from the thermocycler and 1μl of RNase H was added to each sample. Tubes were
returned to the thermocycler for another 20 minutes at 37°C. cDNA tubes were then
stored at -20°C until analysis.
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Primer Formation
To create gene primers, the NCBI website was utilized to obtain sequences for
the Mus musculus species. The longest variant was used to create primers with
sequence alignment performed to ensure the presence of homologous sequences
within all known transcript variants. DNA folding assays were conducted at 61°C and
65°C on the longest variant using the mfold web server by The RNA Institute College of
Arts and Sciences University of Albany. Ionic conditions were set to 50mM of Na+ and
2mM of Mg+. The 65°C assay was analyzed for open sequence areas greater than
100bp that did not contain secondary structures. Identified sequences were then
compared against the 61°C assay to confirm no secondary structures were present at
varying temperatures. The entire primer sequence was cleaned using The Bio-Web and
then transferred to the Integrated DNA Technologies (IDT) website to compare potential
primer sequences to other genes within the Mus musculus species. Primer parameters
was set to a melting point between 60°C to 70°C, guanine/cystine content between 50%65%, and a primer size between 18-30 base pairs. In addition, the entire amplicon
length was set to include primers between 90 and 120 base pairs. All primers were
created to span at least one exon junction. Primers containing hairpin loops that occur
above 45°C or had transcript similarities above 66% were disregarded. Alignment
analysis was performed between the longest variant and all known additional transcript
variants using the IDT alignment tool. Potential primer sequences that were not
identified within all known transcripts were eliminated. From the remaining potential
primer list, two primers for each gene were ordered through IDT and the one utilized in
this study is listed below (Table 1).
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Table 1. Primer sequences for genes used in this study
Target or
Reference
B2M

Primer Sequence

Genbank
Accession
Number
NM_009735

(f) TGTCTCACTGACCGGCCTGTATGCT
(r) ATTCTCCGGTGGGTGGCGTGAGTAT

BDNF

(f) CCATGGGTTACACCAAGGAAGGCT
(r) GGCCCGAACATACGATTGGGTAGT

NM_007540.4

EFNB2

(f) GAGCCTATCTACTGGAATTCCTCGAAC
(r) TGTCTCCTATCTGTGGGTATAGTACCAG

GAPDH

(f) CCCAATGTGTCCGTCGTGGATCTGAC
(r) CTCAGATGCCTGCTTCACCACCTTCT

GRIN1

(f) GGCTGACTACCCGAATGTCCATC
(r) TAGACGCGCATCATCTCAAACCAG

NM_001372558

GRM8

(f) CGCTCGCGCAGTGATTATGT
(r) CCCAACTATCTGAGCCAATCCA

NM_001361125

HPRT

(f) CAGCGTCGTGATTAGCGATGA
(r) CCTGTCCATAATCAGTCCATGAGG

NM_013556

mTOR

(f) CAGACATGCTTCCAACAACACGAG
(r) TCTCCCGGTCAGTATCCCAGAT

NM_028898

NTRK2

(f) CCGGCTTAAAGTTTGTGGCT
(r) CAAGTCAAGGTGGCGGAAATG

NM_008745

NM_010111
NM_008084.3

Real-Time Quantitative Polymerase Chain Reaction
Ideal temperatures for reactions with Quantabio 5Prime Hotstart Master Mix
enzyme were determined for each primer by an endpoint PCR reaction. A master mix
containing enough enzyme, nuclease-free H2O, and primer for the number of reactions
tested, based on concentrations in Table 2, was created. For each sample, 11.5μl of
master mix and 0.5μl of cDNA created from punched tissue, were added to each test
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tube. Tubes were vortexed and ran in a thermocycler for 40 cycles at temperatures
ranging from 50°C to 62°C. Amplification protocol is shown in Table 3. The ideal
temperatures for reactions using Thermo Fisher Scientific PowerUp SYBR Green
Master Mix for each primer were determined using the same process. The master mix
was created using the following substrate ratios shown in Table 2. Reaction samples
were created by using 17.5μl of master mix and 0.5μl of cDNA from punched tissue.
Tubes were vortexed and ran at 40 cycles with temperatures between 50oC and 62oC
using the protocol outlined in Table 4. Following endpoint PCR, analysis tubes were
created using 3μl of Agilent Technologies Sample Buffer and 1μl of amplified sample.
Reactions were visualized on an Agilent Technologies D100 ScreenTape and Agilent
Tape Station. Ideal temperatures were determined based on the highest peak molarity
value obtained (Table 5).
Table 2. Components of sample reactions for PCR and RT-PCR amplifications for
5Prime Hotstart Master Mix and SYBR Green PowerUp enzymes. Template was not
included in master mix; Instead, it was added individually to each sample test tube.
Substrate
Enzyme
Nuclease-Free H2O
Primer
Template

5Prime Hotstart
Master Mix
5.5μl
4.8μl
1.2μl
0.5μl
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SYBR Green
PowerUp
9.0μl
6.7μl
1.8μl
0.5μl

Table 3. 5Prime Hotstart Master Mix endpoint PCR amplification protocol
Step

Temperature

Duration

1

94°C

2 Minutes
(1 Cycle only)
15 seconds
15 seconds
30 seconds
st

2
3
4

94°C
Ideal Temperature
65°C

Table 4. SYBR Green PowerUp amplification protocol
Step

Temperature

1

50°C

2

95°C

3
4
5

95°C
Ideal temperature
72°C

Duration
2 minutes
(1st Cycle Only)
2 minutes
st
(1 Cycle Only)
15 seconds
15 seconds
1 minutes

Preamplification cycles were determined for each primer by running a cycle
gradient using a nested RT-qPCR method. A master mix was created using the
following substrate ratios shown in Table 2 for 5Prime Hotstart Master Mix enzyme.
Sample reaction tubes were created with 11.5μl of master mix solution and 0.5μl of
cDNA obtained from 500 glutamatergic pyramidal neurons. Tubes were vortexed, and
an endpoint PCR reaction was run at the ideal temperature for each primer using the
indicated thermocycler protocol indicated in Table 3. Tubes were taken off at varying
times between 10 and 20 cycles and used as templates for a RT-qPCR reaction. A new
master mix was made based on the components in Table 2 for SYBR Green PowerUp
Master Mix. RT-qPCR test samples were composed of 17.5μl of master mix and 0.5μl of
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previously amplified sample mixtures placed in a 96 well plate covered with an adhesive
film. A roller and card were used to ensure a strong adhesion to the plate and to create
a seal between each well. Plates were vortexed followed by centrifugation to ensure no
bubbles were present then ran using a BioRad qPCR machine for 40 cycles per the
protocol listed in Table 4. Ideal cycles were determined based on the Ct value (Table 5).
Table 5. Temperature and cycles associated with each primer for preamplification with
5Prime Hotstart Master Mix and qPCR with PowerUp SYBR Green Master Mix
Gene
B2M
BDNF
EFNB2
GAPDH
GRIN1
GRM8
HPRT
mTOR
NTRK2

Preamplification
5Prime Hotstart
60.9°C
15 Cycles
56.9°C
20 Cycles
58.3°C
17 Cycles
54.1°C
12 Cycles
59.1°C
17 Cycles
56.1°C
20 Cycles
52.7°C
20 Cycles
54.8°C
20 Cycles
56.1°C
20 Cycles

RT-qPCR
PowerUp SYBR Green
59.6°C
40 Cycles
61.2°C
34 Cycles
59.3°C
40 Cycles
54.1°C
35 Cycles
59.3°C
40 Cycles
59.5°C
40 Cycles
53.2°C
40 Cycles
53.2°C
39 Cycles
59.5°C
40 Cycles

A concentration gradient for each sample was determined by creating a serial
dilution with cDNA punch. A concentration of 0.5μl sample was created by using 2μl of
distilled H2O and 2μl of cDNA punch. A concentration of 0.25μl sample was created by
using 2μl of distilled H2O and 2μl of sample from the 0.5μl mixture. Additional
concentrations were created following this pattern. A nested RT-qPCR method was
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performed following the same protocol previously mentioned using 0.5μl of the desired
concentration as the template for preamplification reactions.
The cDNA from each mouse sample was analyzed for each gene using the same
nested RT-qPCR methods previously explained. cDNA was diluted with distilled
nuclease-free water in a 2μl:6μl ratio. From the diluted cDNA samples 0.5μl was used
as template.

Statistical Analysis
Statistical analysis was performed using Graphpad Prism Version 8. Fold change
values for quantitative PCR were calculated using Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and Hypoxanthine-guanine phosphoribosyl transferase
(HPRT) as reference genes in the 2-ΔΔCT or Livak method (92). Outliers were determined
using a ROUT test on the 2-fold change within each group. A Q-score less than 1% was
considered statistically significant. A Shapiro-Wilk normality test was used to determine
the presence of a normal distribution of each data set. A p-value of less than 0.05 was
considered statistically significant. A one-way analysis of variance (ANOVA) was used
to conduct intergroup comparisons for each gene if the data set passed the normality
test. For genes where the data set did not pass the normality test, a Kruskal Wallis test
was used for intergroup comparisons. A p-value of less than 0.05 was considered
statistically significant. Gender comparisons were performed using an unpaired
Student’s t-test. Pearson’s correlation analysis was used to determine if gene
correlations were present within the male and female models. A p-value of less than
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0.05 (p<.05) was considered statistically significant for both gender comparisons and
correlation analysis.
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CHAPTER 3. RESULTS
Reference Genes
Analysis with RT-qPCR requires the use of reference genes to analyze changes
of expression in genes of interest for the study. Ideal reference genes demonstrate
equal gene expression levels in all samples and normalize starting values to determine
the extent of expression of other genes for relative comparisons. Cycle threshold (Ct)
values for GAPDH, Beta 2-microglobulin (B2M), and HPRT were analyzed to determine
the best reference genes for the study. The mean Ct values obtained for male and
female samples ranged from 15.91 to 18.48 and all had standard deviations less than
two. Values for B2M were (17.36±1.24) and (15.92±0.50), GAPDH (18.48±1.76) and
(18.20±1.32), and HPRT (17.64±1.29) and (16.34±1.19) for males and females
respectively. A one-way ANOVA of all groups did not reveal any significant differences
for GAPDH (Figure 4A; p = 0.30), B2M (Figure 4B; p = 0.43) or HPRT (Figure 4C; p =
0.29).
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Figure 4. Potential reference gene Ct Values. Ct values for each potential reference
gene normalized to the Ct values obtained for the other two reference genes. A oneway ANOVA was conducted on male WT (N = 5), BTBR (N = 7), and VA (N = 5) and
female WT (N = 4), BTBR (N = 5), and VA (N = 4) for (A) GAPDH (p = 0.30) (B) B2M
(p = 0.43) (C) HPRT (p = 0.29). Bars indicated SD for each sample.

Reference gene correlations are necessary to determine what genes will be used
to normalize target gene expression for a relative comparison between samples.
Correlation analysis of male and female samples together revealed significant positive
correlations between GAPDH and HPRT (r2 = 0.3602, p = 0.0004) as well as between
HPRT and B2M (r2 = 0.3160, p = 0.001). No correlation was found between GAPDH
and B2M (r2 = 0.0036, p = 0.75). Male and female samples were analyzed separately
revealing a loss in significant correlation between HPRT and B2M in both male and
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females. GAPDH and HPRT remained significant in both males (r2 = 0.3153, p =
0.0153) and females (r2 = 0.6318, p = 0.0012); therefore, they were selected as the
reference genes for this study (Figure 5; Panels A-J).
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Figure 5. Correlation between reference genes. Correlation confirms changes in Ct
values are not due to differences in gene expression. (A-C) Linear correlation for all
mouse samples (N = 31). (A) B2M and GAPDH (p = 0.7487) (B) HPRT and GAPDH (p
= 0.0004) (C) HPRT and B2M (p = 0.0010) (D-F) Correlation of genes within male
samples (N = 18) (D) B2M and GAPDH (p = 0.3006) (E) HPRT and GAPDH (p =
0.0153) (F) HPRT and B2M (p = 0.1121) (G-I) Linear correlation within female samples
(N = 13). (G) B2M and GAPDH (p = 0.1121) (H) HPRT and GAPDH (p = 0.0012) (I)
HPRT and B2M (p = 0.0531). [* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001]
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Gene Expression
Expression levels for six genes (BDNF, NTRK2, EFNB2, GRIN1, GRM8, mTOR)
were analyzed in pyramidal neurons collected from the ACC of P21 mice with social
behavior deficits. For both BTBR and VA models, genes were analyzed for males and
females independently as well as combined and compared to control mice to identify
any gene expression changes potentially related to ASD human pathology. In addition,
analysis was conducted between males and females to identify any expression changes
potentially linked to gender. While no significant alterations were observed between any
model or between genders, the study did use relatively low sample numbers.
Gene expression differences of BDNF were calculated for male BTBR (N = 7)
and VA (N = 4) mouse models for comparison to WT control mice (N = 5). A ShapiroWilk normality test determined that BTBR gene expression rates was not normally
distributed between groups. A Kruskal-Wallis test for variance demonstrated no change
in gene expression between males (Figure 6A; p = 0.92). Gene expression differences
for females utilized a sample size of N = 4 for WT and VA models and an N = 5 for
BTBR. The Shapiro-Wilk test determined that gene expression data was normally
distributed among the three groups. A one-way ANOVA of the female models revealed
no statistical differences between the groups (Figure 6B; p = 0.86). A combination of
both female and male BDNF gene expression data was not normally distributed among
the groups. A Kruskal-Wallis test indicated that no differences were found for BDNF
gene expression (Figure 6C; p = 0.92). Gender comparisons for BDNF gene expression
using an unpaired Student’s t-test revealed no differences between males and females
for the WT (p = 0.90), BTBR (p = 0.38), and VA (p = 0.50) (Figure 6D).
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Figure 6. RT-qPCR analysis of BDNF expression. A Kruskal-Wallis test (p = 0.92) for
BDNF expression in males between the three groups (WT = 5, BTBR = 7, VA = 4) (B) A
one-way ANOVA (p = 0.15) for BDNF gene expression in females for three groups (WT
and VA, N = 4, and BTBR N = 5). (C) All samples were combined, and a Kruskal-Wallis
(p = 0.92) was used to evaluate differences between WT (N = 9), BTBR (N = 12), and
VA (N = 8) groups. (D) Gender analysis was performed using a Student’s t-test revealed
no differences between WT (p = 0.90), BTBR (p = 0.38), and VA (p = 0.50).

Gene expression of NTRK2 within male was determined for BTBR (N = 7) and
VA (N = 5) as compared to WT (N = 5). A Shapiro-Wilk normality test determined that
gene expression was normally distributed among groups. A one-way ANOVA of the
male models revealed no statistical differences between the groups (Figure 7A; p =
0.48). Gene expression differences for females utilized a sample size of N = 4 for WT
and VA and N = 5 for BTBR. The Shapiro-Wilk test determined that the female gene
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expression data was normally distributed among the three groups. A one-way ANOVA
of the female models revealed no statistical differences between groups (Figure 7B; p =
0.08). A combination of both male and female NTRK2 gene expression data
demonstrated normal distribution among the groups. A one-way ANOVA indicated that
no differences were found for NTRK2 gene expression (Figure 7C; p = 0.82). Gender
comparisons for BDNF gene expression using an unpaired Student’s t-test revealed no
differences between males and females for the WT (p = 0.68) and BTBR (p = 0.56).
Statistically significant differences in gene expression were identified for VA (P = 0.02)
when compared between males and females (Figure 7D).
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Figure 7. NTRK2 expression. A one-way ANOVA (p = 0.48) was used to evaluate
NTRK2 gene expression for males between the three groups (WT = 5, BTBR = 7, VA =
5) (B) A one-way ANOVA (p = 0.08) was used to determine if changes for NTRK2 were
present in females between the three groups (WT = 4, BTBR = 5, VA = 4). (C) When all
samples were combined, a one-way ANOVA (p = 0.83) was used to evaluate
differences between WT (N = 9), BTBR (N = 12), and VA (N=9) groups (D) Gender
analysis was performed using a Student’s t-test to evaluate WT (p = 0.68), BTBR (p =
0.56) and VA (p = 0.02) NTRK2 expression differences.

Gene expression differences of EFNB2 were calculated for male BTBR (N = 7)
and VA (N = 5) mouse models for comparison to WT control mice (N = 5). A ShapiroWilk normality test determined that gene expression rates were normally distributed
between the three groups. A one-way ANOVA demonstrated no significant changes in
gene expression between the models (Figure 8A; p = 0.17). Gene expression
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differences for female models utilized a sample size of N = 4 for WT and VA models and
an N = 5 for BTBR. The Shapiro-Wilk test determined that female gene expression data
was normally distributed among the three groups. A one-way ANOVA revealed no
statistical differences between groups (Figure 8B; p = 0.47). Upon combining both
female and male EFNB2 expression it was found that the data was not normally
distributed among the groups using the Shapiro-Wilk test. A Kruskal-Wallis test
indicated that no differences were found for EFNB2 gene expression (Figure 8C; p =
0.28). Gender comparisons of EFNB2 expression using an unpaired Student’s t-test
revealed no differences between males and females for the WT (p = 0.63) and BTBR (p
= 0.69) (Figure 8D). Statistical differences were identified in the VA (Figure 8D; p =
0.02)
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Figure 8. Expression of EFNB2. (A) A one-way ANOVA (p = 0.17) was used to evaluate
EFNB2 gene expression differences in males between the three groups (WT = 5, BTBR
= 7, VA = 5) (B) A one-way ANOVA (p = 0.47) was used to determine EFNB2
expression differences in females between each group (WT = 4, BTBR = 5, VA = 4) (C)
When all samples were combined, a Kruskal-Wallis test (p = 0.28) was used to
determine gene expression differences between WT (N = 8), BTBR (N = 12), and VA (N
= 8) EFNB2 gene expression. (D) Gender analysis using a Student’s t-test to determine
statistical differences between WT (p = 0.63), BTBR (p = 0.69) and VA (p = 0.02).

Gene expression differences of GRIN1 were calculated for BTBR (N = 7) and VA
(N = 5) as compared to the WT (N = 5). A Shapiro-Wilk normality test determined that
the GRIN1 expression rates were normally distributed between the three groups. A oneway ANOVA demonstrated no change in expression between males (Figure 9A; p =
0.29). Gene expression differences for females utilized a sample size of N = 4 for WT
and VA models and an N = 5 for BTBR. The Shapiro-Wilk test determined normal
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distribution between the three groups. A one-way ANOVA of the female models
revealed no statistical differences between groups (Figure 9B; p = 0.25). A combination
of both female and male GRIN1 gene expression data was normally distributed among
the groups using the Shapiro-Wilk normality test. A one-way ANOVA indicated that no
differences were found for GRIN1 expression (Figure 9C; p = 0.25). Gender
comparisons for GRIN1 gene expression using an unpaired Student’s t-test revealed no
differences between males and females for the WT (p = 0.93), BTBR (p = 0.28), and VA
(p = 0.27) animals (Figure 9D).
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Figure 9. GRIN1 expression. A one-way ANOVA analysis (p = 0.29) was conducted
using males to identify GRIN1 gene expression differences between WT (N = 5), BTBR
(N = 7), and VA (N = 5) animals. (B) Gene expression differences in females was
interrogated using a one-way ANOVA (p = 0.94) between WT (N = 4), BTBR (N = 5)
and VA (N = 4). (C) Analysis of all mice using a one-way ANOVA (p = 0.25) for WT (N =
9), BTBR (N = 12), and VA (N = 9) to determine gene expression differences in GRIN1.
(D) Gender comparisons using an unpaired Student’s t-test did not reveal any
expression differences between males and females within WT (p = 0.93), BTBR (p =
0.28), or VA (p = 0.27) for GRIN1.
Gene expression differences for GRM8 were analyzed for BTBR (N = 6) and VA
(N = 4) mouse models for intergroup comparisons to WT control mice (N = 5). A
Shapiro-Wilk normality test determines that WT, BTBR, and VA gene expression values
for GRM8 were not normally distributed in male animals. A non-parametric KruskalWallis test for variance demonstrated no change in gene expression between males
(Figure 10A; p = 0.69). Gene expression differences for females utilized a sample size
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of N = 5 for WT and VA models and an N = 5 for BTBR. The Shapiro-Wilk test
determined that the female BTBR gene expression data was not normally distributed
among the three groups. A Kruskal-Wallis test demonstrated no changes in gene
expression between the groups (Figure 10B; p = 0.52). Upon combining both female
and male GRM8 gene expression data was not normally distributed among the groups.
A Kruskal-Wallis test indicated no difference were found for GRM8 gene expression
(Figure 10C; p = 0.73). Gender comparisons for GRM8 expression using a Student’s ttest revealed no differences between males and females for WT (p = 0.65), BTBR (p =
0.33), or VA (p = 0.96) animals (Figure 10D).
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Figure 10. Analysis of GRM8 expression. (A) A Kruskal-Wallis test (p = 0.69) was used
to examine differences in GRM8 gene expression for males between the three groups
(WT = 5, BTBR = 6, VA = 4) (B) A Kruskal-Wallis test (p = 0.52) for variance was used
to evaluate GRM8 in females (WT = 4, BTBR = 5, VA = 4) (C) When all samples were
combined, a Kruskal-Wallis test (p = 0.73) was used to examine differences between
WT (N = 9), BTBR (N = 9), and VA (N = 8) animals. (D) Gender analysis using a
Student’s t-test for WT (p = 0.65), BTBR (p = 0.33), and VA (p = 0.96).
Gene expression differences of mTOR expression was calculated for BTBR (N =
7) and VA (N = 5) mouse models for comparison to WT control mice (N = 5). A ShapiroWilk normality test demonstrated that mTOR gene expression rates were normally
distributed between groups. A one-way ANOVA demonstrated no changes in
expression between males (Figure 11A; p = 0.82). Gene expression differences for
females utilized a sample size of N = 5 for WT and VA models and an N = 5 for BTBR.
The Shapiro-Wilk test determined that the female gene expression data was normally
56

distributed among the three groups. A one-way ANOVA of revealed no statistical
differences between groups (Figure 11B; p = 0.87). The combination of both male and
female mTOR gene expression data was not normally distrusted among the groups. A
non-parametric Kruskal-Wallis test indicated that no differences were found for mTOR
expression (Figure 11C; p = 0.76). Gender comparisons for mTOR expression using an
unpaired Student’s t-test revealed no differences between males or females for the WT
(p = 0.58), BTBR (p = 0.25), or VA (p = 0.91) (Figure 11D).
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Figure 11. mTOR expression. (A) A one-way ANOVA (p = 0.82) for mTOR expression
for males between the three groups (WT = 5, BTBR = 7, VA = 5) (B) A one-way ANOVA
(p = 0.76) was used to evaluate mTOR gene expression in females for any group (WT =
5, BTBR = 5, VA = 4) (C) When all samples were combined, a Kruskal-Wallis test (p =
0.76) was used for mTOR gene expression evaluation between WT (N = 9), BTBR (N =
12), and VA (N = 9). (D) Gender analysis using a Student’s t-test revealed no significant
differences between WT (p = 0.58), BTBR (p = 0.25), and VA (p = 0.91).
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Correlations
Correlation analysis was performed between all genes in this study using a Pearson’s
correlation test. Analysis of male samples identified three statistically significant positive
correlations between NTRK2 and EFNB2 (r2 = 0.29, p = 0.02), NTRK2 and GRIN1 (r2 =
0.49, p = 0.001), and EFNB2 and GRIN1 (r2 = 0.57, p = 0.002) (Figure 12; Panels A-C).
A Pearson’s correlation analysis of the female gene expression data revealed a
significant negative correlation between BDNF and GRIN1 (r2 = 0.63, p = 0.001) (Figure
12D).
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Figure 12. Correlation of genes. Significant positive correlations were identified with a
Pearson’s correlation test for NTRK2 (N = 17), EFNB2 (N = 16), and GRIN1 (N = 17)
within the male models. (A) EFNB2 and NTRK2 (p = 0.02) (B) NTRK2 and GRIN1 (p =
0.001) and (C) GRIN1 and EFNB2 (p = 0.002). (D) A significant negative correlation (p
= 0.001) was identified with a Pearson’s correlation for BDNF (N = 13) and GRIN1 (N =
13) within the female samples.
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CHAPTER 4. DISCUSSION
In this study, the expression rates of six genes associated with neuronal
differentiation, plasticity, and survival were quantified from glutamatergic pyramidal
neurons from the ACC for mice with social behavioral deficits. These genes were
specifically chosen based on their association with the BDNF signaling pathways where
abnormalities have already been observed in human patients diagnosed with ASD. A
list of functions for each gene analyzed can be found in the Appendix Table A.
BDNF’s role in survival and growth of neurons has made it a common target of
study in ASD. The overarching goal of this study was to determine if using enriched cell
populations would illuminate the pathology of BDNF-related gene expression in animal
models of ASD. No changes were identified in BDNF expression in glutamatergic cells
from the ACC using the VA or BTBR animal models in this study. Although growing,
support for BDNF’s role in ASD is incompletely characterized at present. The
postmortem literature includes studies with extremely small sample sizes to report
reductions of BDNF protein expression in the frontal cortex, increases in the dorsolateral prefrontal cortex, and no changes in lobule VI of the cerebellum in BDNF in ASD
when compared to TD controls (71,93–95). Two studies have used laser captured
granule cells from the cerebellum and glutamatergic cells from the ACC of human ASD
donors to find no changes in BDNF gene expression when comparing to TD brain
donors (64,93). In the ASD animal model literature, analysis of both BDNF and BDNF
protein in VA fetal offspring showed significant increases in both gene and protein at 3
and 6 hours post VA injection, that diminished after 24 hours (96). Additionally,
increases in BDNF expression followed by a rapid decline after 30 hours post VA
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exposure was found using rat cortical slices (91). Gene expression changes of BDNF in
the offspring of VA dams was brain-region specific with decreased expression reported
in the somatosensory cortex and no changes found in the hippocampus (97). The
studies here did not find any alterations in BDNF in cells taken from the ACC of VA
offspring. It is tempting to speculate that variations in BDNF expression induced
changes in pyramidal neurons of the offspring immediately following VA exposure but
returned to baseline levels before samples were obtained. BTBR mice have shown both
increases using whole brain fetal homogenates and hippocampal decreases in BDNF
gene expression when compared to WT control mice (98–100). The findings here found
no BDNF gene expression changes in ACC glutamatergic neurons in the BTBR mice
when compared to wild-type control mice. Overall, gene expression changes of BDNF
were not found in laser captured glutamatergic neurons in the ACC from 21-day old
male and female mice from either animal model in this study. The lack of change in
BDNF here could be attributed to the limitation of investigating a single cell type, using
inappropriate animal models for this pathway, unaffected brain area, initiation of timedependent expression changes or interference by additional substrates of downstream
signaling pathways of BDNF.
The major BDNF protein receptor trkB encoded for by NTRK2 was the most
important molecule in this study. Previously, our laboratory used laser captured
glutamatergic cells from the ACC of human ASD donors to identify significant decreases
in NTRK2 expression when compared to TD brain donors (64). It was postulated that
the changes in NTRK2 expression in humans may be recapitulated in the animal
models. This study did not identify any changes in NTRK2 expression in pyramidal
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neurons from the ACC of either the VA or BTBR animal models. Previous findings in
ASD donors have alluded to changes in the activation of the signaling cascades
associated with BDNF, but it has not been conclusively proven to result from changes in
NTRK2 or trkB signaling. Unfortunately, very few studies using postmortem ASD
samples have been conducted for NTRK2 expression. Postmortem studies using a
small study number of males and females (N = 11) reported decreases in the trkB
protein in the fusiform gyrus (101,102). The animal literature for the BTBR model has
revealed contradictory findings for trkB expression. One study reported decreased
expression rates for trkB protein within the hippocampus but no changes within the
cortex (103). A second study indicated no changes in NTRK2 expression or trkB protein
expression within the hippocampus (104). The studies here did not find any alterations
in NTRK2 in cells obtained from the ACC of BTBR or offspring of VA mice. Analysis of
trkB have identified two primary trkB isoforms, full-length trkB (trkB.FL) and truncated
trkB (trkB.T1). The ratio of trkB isoforms found on cells can significantly alter neuronal
development. BDNF functions are carried out upon binding to trkB.FL leading to the
formation of a homodimer. Heterodimerization between trkB.FL and trkB.T1 will result in
a failure to initiate the three signaling cascades. In addition, homodimerization of
trkB.T1 has been shown to increase dendritic filopodia (105). The primer used in this
study was unable to differentiate between the trkB isoforms. It is tempting to speculate
that changes in NTRK2 were present, but undetectable due to primer binding
specificities. Overall, NTRK2 gene expression changes were not found in LCM
pyramidal neurons in the ACC from 21-day old male and female mice from either animal
model. The lack of change in NTRK2 found here could be a result of the limitation of
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single-cell type analysis, unaffected brain area, analysis of inappropriate animal models,
lack of primer binding specificity, or the impediment of additional substrates found
downstream of the trkB signaling cascades.
ASD literature consistently suggests that abnormalities are present within
synaptic components. However previous studies have yet to identify definitive evidence
supporting this claim. Since BDNF and trkB binding initiate numerous downstream
pathways, ligand and receptor pathologies within these molecules are often considered
obvious targets of dysregulation; It was chosen in this study to evaluate molecules
associated with BDNF-trkB signaling that exhibit a role in excitatory and inhibitory
neuronal development. Alterations in these molecules can have substantial effects
during critical developmental time periods that have the possibility of contributing to
ASD development. It was thought that pathology might be identified downstream of the
time of the possible insult.
It is known that the downstream molecule of mTOR in involved in synaptogenesis
of both axons and dendrites. The increased dendritic spine density observed in ASD
has led to the speculation that irregularities within mTOR complexes may induce
neuronal changes. In the current study, no changes were identified in mTOR expression
within the glutamatergic cells from the ACC of either the BTBR or VA models. The
implication of the mTOR gene and protein involvement in ASD pathology was initiated
from studies where higher mTOR activity demonstrated decreased autophagy and
increased spine densities (41,68). However, protein studies using the fusiform gyrus (N
= 11) in postmortem ASD tissue showed decreased phosphorylation of mTOR proteins
(102). Analysis of BTBR models have demonstrated behavioral and protein changes
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associated with mTOR dysregulation. Behavioral studies using BTBR mice that have
been treated with rapamycin, an mTOR inhibitor, have shown a reduction in the
presence of social deficits (106). The studies here did not find any alterations in mTOR
gene expression in cells taken from the ACC of BTBR offspring. Within prenatally
exposed VA rats, quantification of mTOR proteins revealed increased levels of mTOR
within the prefrontal cortex, hippocampus, and cerebellum as opposed to decreases in
protein expression within the fusiform gyrus (102,107). In addition analysis of autophagy
proteins associated with mTOR activation revealed decreases in VA offspring (107). In
the current study, no alterations in mTOR expression was observed within the
glutamatergic neurons obtained from the ACC of VA offspring. Overall, gene expression
changes of mTOR were not found in laser captured glutamatergic neurons in the ACC
from 21-day old male and female mice from either animal model. The lack of changes
could be attributed to analysis of an unaffected brain region, the utilization of
inappropriate animal models, the limitation of using the LCM method, or an overall lack
of dysregulation within this specific substrate.
The EFNB2 is a target gene of interest due to the multiple functions its protein,
EFNB2, influences during neuronal development and synaptic maintenance. The
association of EFNB2 with recruiting and anchoring ionotropic glutamate receptors to
the synaptic membrane are of interest when analyzing the excitatory aspects of
neuronal development. Studies of this gene have yet to be performed in postmortem
ASD brain tissue or ASD animal models. But, studies using knock-down mice exhibiting
decreased expression of EFNB2 demonstrated a decrease in synaptic density, fewer
specializations associated with the presynaptic terminal, and an abnormally low
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expression of synapse synthesin-1 required for cellular migration (108). Knock-out
mouse studies demonstrated a decrease in synaptic transmission in the absence of
EFNB2 as evidenced by decreases in miniature excitatory postsynaptic currents (109).
A second study analyzing the hippocampus of knock-out mice identified decreases in
LTP (110). Reduced dendritic branching, reduced spine diameter, and impaired longterm potentiation have been demonstrated in EFNB2 knock-out mouse strain (111).The
studies here did not find any alterations in EFNB2 in the cells collected from the ACC
from 21-day old mice. The functions of EphrinB2 and its receptor EphB are also
responsible for neuronal functions during early development. The receptor-ligand
binding is also responsible for the initial interactions of the pre-synaptic and postsynaptic filopodia followed by the recruitment of required synaptic components. Mutant
mice demonstrate a lack of migration during neuronal development (112). It is tempting
to speculate that variations of EFNB2 expression could be dysregulated during early
neuronal development, but additional studies would need to be conducted on offspring
collected during the fetal stages.
Potential changes in GRIN1 are of interest due to the major neuronal functions
associated with NMDA receptors. The presence of the zeta-1 subunit allows for
neurotransmission of excitatory neurons, synaptic plasticity, and the refinement of
excitatory synapses via functional NMDA receptors. No changes were identified in
GRIN1 expression in the pyramidal neurons from the ACC using the VA or BTBR
animal models in this study. The postmortem literature has used small sample studies
to report a decreased trend in gene expression from pyramidal neurons of the ACC
(64). Animal studies involving knock-out mice have demonstrated that NMDARs are
64

responsible for eliminating excess axonal inputs. In addition, neurons of the thalamus
lacking functional NMDA receptors experience developmental arrest as well as
prohibiting increased expression of other ionotropic glutamate receptors, specifically
AMPA receptors, within the cell (109). Additional knock-out studies found that the
absence of NMDA receptors within the hippocampus resulted in increases in AMPA
(113). Behavioral studies using a mouse model with a genetically mutated GRIN1 gene
have shown abnormal social behaviors like a preference in interacting with inanimate
objects and hyperactivity (114).
Glutamate receptors that upon activation result in decreases in glutamate release
from presynaptic terminals play a vital function in maintaining the balance between
inhibitory and excitatory signals by preventing excitotoxicity. The metabotropic
glutamate receptor 8 (mGluR8) encoded by the gene GRM8 is a G-protein that is
coupled to Gi/o proteins that affect synaptic transmission by inhibiting the Ca2+ activation
of adenylyl cyclase. This inhibition results in the decrease of cAMP ultimately affecting
the amount of trkB proteins trafficked to the surface of the cell. The limited trkB proteins
result in decreases in signaling cascade activation prohibiting the release of glutamate
(115). Although it could be considered an upstream element in BDNF-trkB signaling, we
chose to include it in this study due to the importance in excitatory and inhibitory
signaling. Human ASD genetic studies involving 200 families reported that duplications
in the GRM8 gene in 175 of the families resulted in a gene shift affecting the amino acid
composition of the protein (116). Previous postmortem ASD brain tissue analysis using
LCM glutamatergic neurons from the ACC demonstrated non-significant decreases in
expression when compared to TD control donors (64). Studies utilizing BTBR or VA
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ASD animal models to study GRM8 have not been conducted, but behavioral analysis
studies using Glu8 knock-out mice in open-field and plus-maze tests indicated that
anxiety-like behaviors were exaggerated (117). The current study did not find any
alterations in GRM8 gene expression in the offspring of VA or BTBR offspring.
Gene expression differences between males and females was conducted to
determine differences that may indicate pathophysiological changes associated more
often with specific genders. This vital component of ASD research is substantially
understudied with regard to gender comparisons in the literature. Identifying different
molecular dysregulations with a gender-association can help to explain the increased
prevalence rates towards males in the development of ASD. In the current study,
gender comparisons revealed significant expression differences of NTRK2 and EFNB2
in male VA models as compared to females. While analysis of individual genes between
groups of each gender was not significant, analyzing expression levels between
genders within the groups displayed that the male and female mice have significantly
different expression levels of NTRK2 and EFNB2. The combination of small increases
of NTRK2 expression within the females and the small decreases within the males
created a gap large enough to meet significance. In addition, gender analysis of EFNB2
also demonstrated different dysregulations between the male and females. Upon further
analysis it appears that the expression of EFNB2 holds relatively constant between WT
and VA females, but the expression observed in males decreases enough in the VA
model to meet significance. The fact that females are able to maintain their normal
expression rates while the males experience downregulation could provide support for
the theory that females have protective mechanisms that prevent ASD development.
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Gene correlation analysis was conducted on genes within males and females
individually. While single gene analysis revealed no changes within the models, it is
important to determine if regulation between certain genes appears to demonstrate
correlations with other genes. Male analysis detected three significant positive
correlations between NTRK2 and EFNB2, NTRK2 and GRIN1, and EFNB2 and GRIN1.
Female analysis detected a significant negative correlation between BDNF and GRIN1.
These correlations could indicate that the start of the BDNF pathway could be more
tightly interconnected with components of the NMDA-receptors that other genes within
the system. While it appears only small undetectable gene expression differences are
observed within individual genes, tight interconnections could ultimately allow for small
changes in each gene to compound into larger dysregulations throughout the entire
system. However, it is also likely that some other dysregulation occurring outside of the
BDNF-pathway could be the link between these gene correlations.
While it is thought that alterations within these signaling cascades lead to ASD
development, it is highly unlikely that a single genetic alteration is responsible for this
disorder. Genetic studies attempting to identify causes of ASD, have identified hundreds
of possible genes that could influence ASD development (118). In addition, the
heterogeneity of ASD behaviors and severity observed between cases are likely due to
a combination of different genetic abnormalities as well as differences in the extent of
genetic changes.
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Limitations
While this study offers unique insight for the field of ASD research, there are
several limitations that must be taken into consideration. First, the animal models within
this study are not universally accepted as suitable behavioral models since currently
ASD has no accepted animal model for the core behavioral features. ASD is a
heterogenic disorder with multiple subgroups most likely resulting from different
combinations of genetic and environmental etiologies. It is unlikely that a single animal
model will ever be found to encompass all risk factors and behaviors associated with
ASD. The animal models used in this study were chosen based on their relationship to
BDNF and glutamatergic neurotransmission. It is clearly a need in the literature whether
the same molecular mechanisms underlying animal behavior are the same as those
associated with behavioral abnormalities observed in human ASD. Secondly, while this
method of tissue acquisition allows for very specific analysis of pyramidal neurons it
prevents investigations of other cell types. Cell-specific studies of GABAergic neurons
and astrocytes are needed to determine if the pathways demonstrate BDNF related
pathology. Additionally, the study was plagued with small sample size due to the pilot
nature of the study and the COVID-19 pandemic; therefore, increases in sample
number may reveal significant changes in gene expression. Finally, analysis was limited
to only the gene expression. Protein analysis would determine if the quantity, structure,
or function of the gene products are altered.
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CHAPTER 5. CONCLUSION
ASD is a complex neurodevelopmental disorder that likely results from a multifactorial etiology. The complex origin of ASD has resulted in a multitude of genetic
abnormalities that have been shown through sequencing studies using blood from those
diagnosed with ASD and compared to undiagnosed age-matched controls. The varying
behavioral phenotypes observed in human ASD likely result from multiple gene
alterations. Animal models displaying behavioral deficits were used to evaluate the
expression of genes within the excitatory neurons of the ACC associated with the BDNF
pathway. This study did not identify any significant differences in gene expression
between the three models. The sample sizes within this study were low. Statistically
significant differences were identified in gender comparisons of the VA models for
NTRK2 and EFNB2. Gender studies using ASD tissue are limited but are a vital
component to fully understanding the high prevalence towards males. The differences in
gene regulation between NTRK2 and EFNB2 could indicate differences in the neuronal
connectivity between males and females that are important in developing ASD. In
addition, significant positive correlations were identified for male models involving
NTRK2, EFNB2, and GRIN1. Female correlation studies revealed a significant negative
correlation between BDNF and GRIN1. The increased number of correlations observed
within males could indicate tighter interconnections between components of this BDNFpathway. Tighter interconnections could allow for small changes in one gene to
influence changes in other genes leading to the large dysregulation observed in ASD.
The overarching goal of the study was to determine if the BDNF-associated pathology in
patients with ASD could be recapitulated in these particular animal models of the
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disorder. It was determined from the studies that these models would not be suitable for
future therapeutic studies that targeted the BDNF signaling pathway in ASD behaviors.
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APPENDICES
Appendix A: Identification of All Genes Used in This Study
Gene

Function

B2M

Encodes for Beta-2 Microglobulin which is a protein found on all cells
within the body which stabilizes MHC molecules
Neurotrophin that binds to trkB to activate MAPK, PLCγ, and PI3K
signaling pathways leading to synaptogenesis, neuronal proliferation,
plasticity, and survival.
Encodes for ephrinB2 protein which binds to the EphB receptor
which aids in synaptogenesis in early development and glutamate
receptor stabilization in late development.
Encodes for glyceraldehyde 3-phosphate dehydrogenase which is an
enzyme found in all cells that breaks down glucose
Encodes for the required NMDA-1 subunit for NMDA receptors which
plays a role in transmission of excitatory neurons and synaptic
plasticity.
Encodes for metabotropic glutamate receptor 8 which inactivates
adenylyl cyclase to prevent overstimulation of NMDA receptors.
Encodes for Hypoxanthine-guanine phosphoribosyltransferase which
plays a role in the formation of purine nucleotides
Encodes for the mTOR protein which complexes with other proteins
to affect cell survival and synaptogenesis by controlling autophagy
and protein synthesis
Encodes for the trkB receptor that upon binding activates MAPK,
PLCγ, and PI3K signaling pathways leading to synaptogenesis,
neuronal proliferation, plasticity, and survival.

BDNF

EFNB2
GAPDH
GRIN1
GRM8
HPRT
mTOR

NTRK2

82

Appendix B: Mapping Images for Each Animal Used in This Study

83

84

85

86

87

VITA
MISTY M. OWENS

Education:

B.S., Health Science, East Tennessee State University,
Johnson City, Tennessee, 2016
M.S., Biology, East Tennessee State University,
Johnson City, Tennessee, 2020

Professional Experience: Graduate Assistant, Department of Health Sciences, East
Tennessee State University, 2018-2020
Student Researcher, Department of Health Sciences, East
Tennessee State University, 2018-2020

Honors and Awards:

Appalachian Student Research Forum, 1st Place, East
Tennessee State University, 2019

88

